Combining its discoveries relating to exosomes and Exerkines™, Exerkine Corporation is developing a new class of breakthrough therapies that have broad health care implications. Preclinical results show that our discoveries and techniques provide significant health and quality of life improvements over current management strategies for genetic and aging-associated diseases.
Genetic Diseases
Genetic diseases are often the most difficult diseases to diagnose and treat. Caused by an underlying defect in genes that are present at birth, current management strategies aim to deliver drugs that address secondary symptoms, but don’t attack the underlying genetic defect. Our therapies mitigate these secondary symptoms by correcting the underlying genetic defect. Our therapies have the potential to deliver the blueprint of the normal gene to affected areas, providing the body with the tools to restore normal function and improve health.
Current research and development is investigating the impact of our therapies on:
- Lysosomal Storage Diseases
- Mitochondrial Diseases
- Cystic Fibrosis
Aging Associated Diseases
Aging-associated diseases are diseases that increase in frequency with an increasing rate of biological aging, or senescence. Senescence involves the gradual deterioration of bodily functions. This gradual deterioration leads to cardiovascular issues, diabetes and dementia. Our therapies seek to address specific complications associated with senescence by supplying the body with biological compounds or mediating biological systems that exert positive health effects.
Current research and development is investigating the impact of our therapies on:
- Alzheimer, Parkinson’s and other Neurodegenerative Diseases
- Cardiovascular Diseases
- Obesity and Type 2 Diabetes